Interview 11 Sep 2018 How To Break Into The Crowded Immuno-Oncology Space The field of immuno-oncology promises to make anti-cancer treatments more effective than ever. But in this crowded field, many companies struggle to make therapies that not only are effective and safe, but that can also be scaled-up, manufactured and commercialized. Helen Tayton-Martin, Chief Business Officer at the biotech company Adaptimmune, shares her advice on how […] September 11, 2018 - 6 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 10 Sep 2018 Cambridge Biotech Targets Artificial Pancreas Market With Fast Insulin and Stable Glucagon UK biotech Arecor has raised €6.7M to help fund development of its extra-fast insulin and stable glucagon products for people with insulin-dependent diabetes. The speed of action of insulin has been a limiting factor for development of the artificial pancreas — a combined insulin pump and glucose monitor that would allow real-time control of blood […] September 10, 2018 - 2 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 10 Sep 2018 Update: Non-Invasive Glucose Monitoring Device Moves Forward With Series B Funding Update (10/09/2018): RSP Systems has raised an additional €3.85M that raises the total amount of its Series B fundraising to €10.35M. The funds will be used to run clinical trials with the company’s device, which measures blood sugar without the need for finger-pricking. Published on 11/06/2018 RSP Systems has raised €6.5M in the first closing […] September 10, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
Best in Biotech 10 Sep 2018 10 Biotech Companies in Berlin You Should Know The vibrant startup scene of the German capital has attracted many biotechs to make it their home. Here are ten biotech companies in Berlin to keep an eye on. Well-known for its history and rich cultural scene, Berlin is also a hotspot for startups of all kinds (including us!). As the headquarters of the successful […] September 10, 2018 - 6 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 6 Sep 2018 More Brexit Bad News: EMA Pulls Contracts Early From UK Regulatory Body The European Medicines Agency (EMA) has pulled all contracts with the UK’s medical regulation body ahead of the UK withdrawing from the EU next year. Until 2018, the EMA has relied on the UK Medicines & Healthcare products Regulatory Agency (MHRA) to assess 20–30% of its drugs on a contract basis, work worth approximately €15.6M […] September 6, 2018 - 2 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 6 Sep 2018 Insulin Combo Reduces After-Meal Sugar Spikes in Type 1 Diabetics In the midst of a legal litigation with Eli Lilly, Adocia has released Phase 1 data showing its insulin combo can outperform Lilly’s fast-acting insulin in keeping sugar levels low after a meal. The trial, which recruited 24 type 1 diabetics, studied the effect of Adocia’s BioChaperone pramlintide insulin on glucose levels right after […] September 6, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 5 Sep 2018 Cassava Plants Gene Edited Using CRISPR to Produce Waxy Starch A team of European researchers applied CRISPR-Cas9 gene editing technology to engineer cassava plants that produce a modified type of starch, in demand for both cooking and industrial processing. The team also managed to speed up the flowering of the plants by introduction of a gene from Arabidopsis plants, which they hope will allow more […] September 5, 2018 - 3 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 5 Sep 2018 RNA Therapy Improves Vision in Patients with Rare Genetic Blindness Dutch company ProQR has released data from a Phase I/II trial showing its RNA therapy can improve the vision of people with a rare form of hereditary blindness. The clinical trial recruited 10 people with the rare disease Leber’s congenital amaurosis 10. Caused by mutations in a gene called CEP290, this condition leads to […] September 5, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 4 Sep 2018 The EMA Approves the First Nanobody from Ablynx Update: The EMA has officially approved Cablivi for the treatment of adults with acquired thrombotic thrombocytopenic purpura, following its earlier recommendation in June. The drug has also been accepted for priority review by the US FDA, with a decision due on 6 Feb 2019. Published 29.6.18 Just a few months after Sanofi acquired Ablynx in a multi-billion euro […] September 4, 2018 - 2 minutesmins - By Editorial Team Share WhatsApp Twitter Linkedin Email
More News! 4 Sep 2018 Semi-Artificial Photosynthesis Method Produces Fuel More Efficiently Than Nature Scientists at the University of Cambridge have developed a new photosynthesis method that combines biological and synthetic components to produce hydrogen using sunlight as the only source of energy. “Natural photosynthesis has evolved to store solar energy and to reduce the greenhouse gas carbon dioxide into sugars, but this process is not very energy […] September 4, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 3 Sep 2018 Oxford Biotech Raises €40M to Deliver Drugs to Hard-to-Reach Targets Evox Therapeutics has raised £35.5M (€39.4M) in a Series B fundraising that has been backed, among others, by the venture arm of Google’s parent company. A spin-out from the University of Oxford and the Karolinska Institute, Evox Therapeutics has raised a large round that will fund the development of its drug delivery technology to […] September 3, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Interview 3 Sep 2018 Moving from Big Pharma to Biotech – Insights from Two Biotech CEOs According to John LaMattina in Forbes last year, more and more senior scientific executives are moving from pharma to small biotechs or startup initiatives. While the jury is out on whether this observation reflects a real trend or not, we at Labiotech are keen to learn about what drives people to make such a move! […] September 3, 2018 - 11 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email